WO2024241086 - PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2024/241086
Publication Date
28.11.2024
International Application No.
PCT/IB2023/061789
International Filing Date
22.11.2023
Title **
[English]
PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF
[French]
INTERFÉRON LAMBDA BOVIN PÉGYLÉ ET SES PROCÉDÉS D'UTILISATION
Applicants **
AMBRX, INC.
10975 North Torrey Pines Road
La Jolla, California 92037, US
Inventors
KNUDSEN, Nickolas
Escondido
California, US
CANNING, Peter
Carmel
Indiana, US
Priority Data
63/504,133
24.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4180 | |
| EPO | Filing, Examination | 50925 | |
| Japan | Filing | 529 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 21335 |
Total: 77544 USD
Abstract[English]
A long-acting conjugated protein comprising a bovine interferon lambda-3 protein conjugated to a water-soluble polymer moiety via a non-naturally encoded amino acid in the protein is described. Also described are methods of protecting ruminant mammals from foot and mouth disease or bovine respiratory disease by administering the long-acting conjugated protein. Bovine interferon lambda-3 protein variants, and variants containing non-naturally encoded amino acids suitable for conjugation to moieties that are capable of extending bovine interferon lambda-3 protein elimination half-life, such as water-soluble polymers, are also described.[French]
L'invention concerne une protéine conjuguée à action prolongée comprenant une protéine d'interféron lambda-3 bovine conjuguée à une fraction polymère hydrosoluble par l'intermédiaire d'un acide aminé non naturellement codé dans la protéine. L'invention concerne également des procédés de protection de mammifères ruminants contre la fièvre aphteuse ou la maladie respiratoire bovine par administration de la protéine conjuguée à action prolongée. L'invention concerne également des variants de la protéine lambda-3 d'interféron bovine, et des variants contenant des acides aminés codés de manière non naturelle appropriés pour la conjugaison à des fractions qui sont capables de prolonger la demi-vie d'élimination de la protéine lambda-3 d'interféron bovine, telles que des polymères hydrosolubles.